Skip to content

Ophthalmology

Establishing new methods of diagnosis for early eye disease to avoid disability, and investigating novel therapeutic approaches

What does this
Theme Involve?

This theme is focused on the molecular mechanisms involved in either the treatment or pathogenesis of retinal neurodegenerative diseases, including glaucoma, Alzheimer’s and diabetes. The aims of the work are to establish new methods of diagnosis of early disease to avoid disability, identify early markers of cell processes in neurodegenerative disease and investigate therapeutic approaches including novel modes of drug delivery and improved treatment strategies.

Partners and Facilities

By joining this theme you will be working clinical and non-clinical researchers from the UCL Institute of Ophthalmology and Moorfields Eye Hospital.

Studying Under This Theme

Projects listed below are available for applicants to include in their 5 project choices. Successful candidates will meet with both primary supervisors from their selection as part of the induction process before being assigned to an allocated research project. To view all available project videos please visit our YouTube channel.

Theme Leader

Prof Francesca Cordeiro
UCL Institute of Ophthalmology

Professor M Francesca Cordeiro, is a clinician scientist. She currently heads the “Glaucoma and Retinal Neurodegeneration Research Group” at the Institute of Ophthalmology, University College London and is an Honorary Glaucoma Consultant Ophthalmologist at the Western Eye Hospital, Imperial College Healthcare NHS Trust in London, where she is Director of the Clinical Trials Research Unit, Chairman of ICORG (Imperial College Ophthalmic Research Group) and Visiting Professor.

She qualified in medicine from St Bartholomew’s Hospital University of London and completed training in general and surgical ophthalmology at Moorfield’s Eye & St Thomas’ Hospitals in London in 2003, following her PhD at UCL in 1998.

Her research is focused on the molecular mechanisms involved in either the treatment or pathogenesis of retinal neurodegenerative diseases, including glaucoma, Alzheimer’s and diabetes. The aims of her group’s work are to establish new methods of diagnosis of early disease to avoid disability, identify early markers of cell processes in neurodegenerative disease and investigate therapeutic approaches including novel modes of drug delivery and improved treatment strategies. She has investigated novel and translational approaches to these problems, and has received a number of awards for her work including Research to Prevent Blindness International Research Scholar Award USA in 2014, an Allergan Glaucoma Achievement Award 2010, the Lewis Rudin Glaucoma Prize 2005 from the New York Academy of Medicine, the 2000 International Glaucoma Review Award, and the 1998 Moorfields Research Gold Medal.

Her research has been funded by the Wellcome Trust since 1996, including a Vision Research Fellowship, a University Award, and most recently a Welllcome Translational Award for the DARC Project.

She serves on a number of international committees including the European Glaucoma Society and EVER and has a special interest in neuroprotection in glaucoma and neurodegenerative diseases, and currently chairs the EGS Neuroprotection SIG. She is on the Editorial Board of various journals including Investigative Ophthalmology, Experimental Eye Research and Scientifica. She has been graduate tutor at UCL and teaches modules for both under and post-graduates.

Available Projects:

A Novel Imaging Biomarker for Retinal Neurodegeneration